Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies

April 22, 2021
OncLive Staff

Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.

Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.

OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director of the Hematopoietic Cell Transplantation Program at Swedish Cancer Institute, to discuss the evolution of PI3K inhibitors in lymphoid malignancies in light of the recent regulatory approval of umbralisib (Ukoniq) for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma.

In our exclusive interview, Pagel discussed the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.